Mariner
APLS

Mariner’s Apellis Pharmaceuticals APLS Stock Holding History

Mariner’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-43,239
Closed -$978K – 3544
2025
Q3 		$978K Buy
43,239
+6,909
+19% +$161K ﹤0.01% 1920
2025
Q2 		$629K Buy
36,330
+23,326
+179% +$432K ﹤0.01% 2158
2025
Q1 		$284K Buy
+13,004
New +$359K ﹤0.01% 2675
2024
Q4 		– Sell
-10,625
Closed -$307K – 3386
2024
Q3 		$307K Sell
10,625
-1,150
-10% -$42.6K ﹤0.01% 2551
2024
Q2 		$452K Sell
11,775
-2,590
-18% -$117K ﹤0.01% 2119
2024
Q1 		$844K Buy
14,365
+464
+3% +$29.6K ﹤0.01% 1633
2023
Q4 		$832K Buy
13,901
+3,460
+33% +$176K ﹤0.01% 1564
2023
Q3 		$397K Buy
10,441
+4,882
+88% +$214K ﹤0.01% 1927
2023
Q2 		$506K Buy
5,559
+501
+10% +$43.2K ﹤0.01% 1736
2023
Q1 		$334K Buy
+5,058
New +$292K ﹤0.01% 1983

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Mariner's APLS Position: Q4 2025 in Review

Mariner sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 43,239 shares — an estimated $978K sold.

Mariner first reported a position in APLS in Q1 2023 and held it in 10 quarters. The position peaked at $978K in Q3 2025. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • Mariner reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Mariner sold 43,239 Apellis Pharmaceuticals shares in Q4 2025, an estimated $978K.
  • Mariner first reported a position in Apellis Pharmaceuticals in Q1 2023 and held it in 10 quarters.
  • Mariner's Apellis Pharmaceuticals position peaked at $978K in Q3 2025.
  • 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on Mariner's 13F filing for Q4 2025, filed 13 Feb 2026.